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Trace of survivin in cancer
Fereshteh Shojaeia, Farshad Yazdani-Nafchia, Mehdi Banitalebi-Dehkordia,
Mohammad Chehelgerdia and Milad Khorramian-Ghahfarokhib
Survivin is one of the most cancer-specific proteins
overexpressed in almost all malignancies, but is nearly
undetectable in most normal tissues in adults. Functionally,
as a member of the inhibitor of apoptosis family, survivin
has been shown to inhibit apoptosis and increase
proliferation. The antiapoptotic function of survivin seems to
be related to its ability to inhibit caspases directly or
indirectly. Furthermore, the role of survivin in cell cycle
division control is related to its role in the chromosomal
passenger complex. Consistent with its determining role in
these processes, survivin plays a crucial role in cancer
progression and cancer cell resistance to anticancer drugs
and ionizing radiation. On the basis of these findings,
recently survivin has been investigated intensively as an
ideal tumor biomarker. Thus, multiple molecular
approaches such as use of the RNA interfering technique,
antisense oligonucleotides, ribozyme, and small molecule
inhibitors have been used to downregulate survivin
regulation and inhibit its biological function consequently.
In this review, all these approaches are explained and
other compounds that induced apoptosis in different
cell lines through survivin inhibition are also reported.
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Introduction
Survivin, the unique member of the inhibitor of apoptosis
(IAP) family, plays a major role both in the cell division
process and in the inhibition of apoptosis (Mita et al.,
2008). Survivin serves its regulatory function in cell
division through its role in the chromosomal passenger
complex (CPC), which regulates microtubule dynamics,
stability, and mitotic progression (Giodini et al., 2002),
and serves its antiapoptotic function through interaction
with multiple proteins such as hepatitis B X-interacting
protein, X-linked inhibitor of apoptosis (XIAP), and
second mitochondrial-derived activator of caspase/direct
inhibitor of apoptosis-binding protein with low Pi (Smac/
DIABLO), which inhibits caspase activation (Peery et al.,
2017). Survivin overexpression has been detected in a
wide variety of malignancies, which results in cell-cycle
checkpoints bypasses and promotion of aberrant pro-
gression of transformed cells, unlike its minimal expres-
sion in normal healthy tissues (Ryan et al., 2009). Survivin
overexpression is correlated with adverse consequences
including tumor aggressiveness, cancer relapse, therapy
resistances (such as radiation therapy and chemotherapy),
and poor clinical outcome (Li et al., 1998). Therefore,
anticancer strategies have currently focused on survivin
status both as a cancer biomarker and as a potential target
for designing new approaches for cancer treatment.
In this review, we introduce recently investigated
survivin-targeted approaches besides different drugs
and compounds that induced apoptosis in cancer cell lines
through survivin downregulation. It is noteworthy, however,
that survivin structure and physiological function are briefly
reviewed.
Survivin structure
The IAPs is one of the well-known apoptosis inhibitor
families consisting of several proteins such as NIAP, XIAP,
Cellular inhibitor of apoptosis protein-1, cellular inhibitor of
apoptosis protein-2, ILP2, livin, baculovirus inhibitor repeat
(BIR)-repeat-containing ubiquitin-conjugating enzyme, and
survivin (Jaiswal et al., 2015). All family members are char-
acterized by a common motif in their structure called the
BIR domain with a length of 70–80 amino acid (LaCasse
et al., 1998). Survivin is the smallest member of this family,
encoded by the baculoviral IAP repeat-containing 5 gene,
consisting of four main exons and localized in the telomeric
region of chromosome 17 (McKenzie and Grossman, 2012).
Along with its major transcript (baculoviral IAP repeat-
containing 5, survivin), which codes the wild-type protein
142 amino acids in length, alternative splicing generates
four more splice variants coding survivin 2a, 2B, 3B, and
ΔEx3, which serve different cell functions (Li, 2005).
Survivin contains one single BIR domain in the N-terminal
region and one coiled–coil motif in the C-terminal region.
The BIR domain is critical for antiapoptotic function,
whereas the coiled–coil motif is considered to interact with
microtubules that are involved in cell division process
(Wheatley and McNeish, 2005). X-ray crystallography
showed that survivin structure forms a bow tie-shaped dimer.
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There is also one zinc finger in its structure formed by four
Zn2+ -binding residues including Cys‐60, Cys‐57, Cys‐84,
and His‐77 that retain survivin integrity (Chantalat et al.,
2000). Survivin is also distinguished from the other IAP
family members by the lack of caspase activation and
recruitment domain and RING finger (really interesting
gene) motifs (Deveraux and Reed, 1999). Figure 1 shows
the different members of the IAP protein family with
diverse domains and lengths.
Role of survivin in cell apoptosis
Before explaining the apoptosis-inhibitory role of survivin,
the apoptosis process is briefly mentioned. Apoptosis is
described by a series of coordinated events called ‘pro-
grammed cell death’ to maintain tissue homeostasis and
protect the cell against particular triggers and conditions
such as cell-cycle arrest, irradiation exposure, and drugs
(such as chemotherapy agents) that cause DNA damage
and cell infection (Elmore, 2007). Apoptosis has through
two intrinsic and extrinsic pathways. In both pathways, the
activation of caspases (cysteine aspartate proteases) is
essential. The active caspase gives rise to cell death through
disruption of the essential cellular proteins such as nuclear
lamina and cytoskeleton, activation of the caspase-activated
domain, and cellular systems deregulation such as DNA
repair (Turk et al., 2000). In the intrinsic pathway, after cell
exposure to a wide range of stimuli such as UV irradiation,
chemotherapy agents, and p53 activation, cytochrome C is
released from the mitochondria and binds to apoptotic
protease activating factor 1 and caspase-9 to form the
apoptosome complex, which leads to caspase-9 activation
(Acehan et al., 2002). The active form of caspase-9 activates
caspase-7 and caspase-3 by cleavage of their prodomains,
all finally resulting in cell death (Wheatley and McNeish,
2005). The extrinsic pathway is initiated after binding of
death ligands such as TNF-related apoptosis-inducing
ligand and FasL to their relative receptors, which leads to
oligomerization of the receptor and recruits Fas-associated
death domain, which is an adaptor protein. Binding of the
death-inducing domain of Fas-associated death domain
with the death-inducing domain of procaspase-8 and
procaspase-10 promotes caspase activation to activate
effector caspase-3, caspase-6, and caspase-7, which finally
leads to cell death (Donepudi et al., 2003). As survivin lacks
caspase activation and the recruitment domain, it cannot
bind to caspase directly; therefore, survivin inhibits apop-
tosis through interaction with the XIAP, which increases
XIAP stability to inhibit caspase-9 activation. Furthermore,
survivin interacts with hepatitis B X-interacting protein and
suppresses caspase-9 activation through blocking apoptotic
protease activating factor 1 recruitment to the apoptosome
(Marusawa et al., 2003). However, Survivin interacts with
Smac/DIABLO (Sun et al., 2005). Smac/DIABLO is a
protein released from the mitochondria after cell exposure
to stimuli, which suppresses the apoptosis-inhibitory func-
tion of IAP by directly binding to them (Du et al., 2000).
Survivin–Smac interaction neutralizes the effect of Smac/
DIABLO on other IAPs, prevents XIAP inhibition by
sequestering Smac/DIABLO, and enhances caspase-
9-mediated cell apoptosis (McKenzie and Grossman, 2012;
Jaiswal et al., 2015) (Fig. 2).
Role of survivin in the cell division process
Survivin expression is high during G2/M phases of the
cell-cycle, whereas a rapid decrease occurs in the G1 phase.
Its expression level is controlled by two cell cycle-dependent
Fig. 1
Structures of IAP protein family members. The IAP family consists of eight antiapoptosis protein including NIAP/BIRC1, c-IAP1/BIRC2, c-IAP2/
BIRC3, XIAP/BIRC4, Survivin/BIRC5, Apollon (BRUCE)/BIRC6, Livin/BIRC7, and ILP2/BIRC8. Survivin with only one BIR domain is the smallest
member of this family. The caspase-inhibitory function of XIAP, NAIP, c-IAP1, and c-IAP2 is associated with a conserved linker peptide (shown in dark grey)
that precedes the BIR2 of these proteins. This peptide inhibits caspase-3 and caspase-3. In addition, in XIAP, the BIR3 domain is responsible for inhibiting
caspase-9 (Mobahat et al., 2014). BIR, baculovirus inhibitor repeat; BRUCE, BIR-repeat-containing ubiquitin-conjugating enzyme; CARD, caspase
activation and recruitment domain; c-IAP, cellular inhibitor of apoptosis protein; IAP, inhibitor of apoptosis; ILP, IAP-like protein 2; NAIP, neuronal apoptosis
inhibitor protein; XIAP, X-linked inhibitor of apoptosis.
2 European Journal of Cancer Prevention 2018, Vol 00 No 00
Copyright r 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
element and cell cycle gene homology region within the
survivin gene promoter (Khan et al., 2017). Survivin plays an
important role in cell cycle progression toward successful
mitosis through CPC formation; also, the role of survivin in
cell division is accompanied by its localization in the cen-
trosome, spindle microtubules, and spindle poles (Giodini
et al., 2002). Survivin dysfunction leads to cell-cycle defects
including impairment of cytokinesis, centrosome dysregula-
tion, and formation of multinucleated cells (Li et al., 1999).
Although overexpression of survivin as a part of this complex
has an impact on microtubule stability through regulation
of the growth rate and microtubule-associated proteins
recruitment, which are regulatory elements in the organiza-
tion of cytoskeleton (Giodini et al., 2002), the CPC maintains
the genomic stability through contributing in several cell
division phases. In the prophase, CPC contributes toward
chromosome structure regulation and cohesion elimination
from chromosomal arms. In the anaphase, the CPC provides
proper chromosomal arm shortening. In the metaphase,
CPC plays a role in microtubule formation, stability,
dynamics, and microtubule–kinetochore attachment as
well as spindle assembly checkpoint activation and, in
cytokinesis, CPC averts tetraploidization through control-
ling the division of the cytoplasm (van der Waal et al.,
2012). The other CPC components are inner centromere
protein, borealin and the enzymatic core, and Aurora B
kinase (van der Waal et al., 2012). The localizations of inner
centromere protein antigen, Aurora B kinase, Borealin,
and survivin are all mutually dependent on each other.
However, survivin plays all substrate, regulator, and adaptor
roles related to Aurora B kinase. Thus, it stimulates kinase
activity and regulates RasGAP in RAS signaling as an
inhibitor of the kinase activity in a complex with survivin
(Wheatley and McNeish, 2005). Furthermore, survivin in
the CPC promotes the movement of complex from the
inner centromere to the midbody during prometaphase
progression to cytokinesis (Jeyaprakash et al., 2007).
Survivin expression in cancer and therapeutic strategies
Survivin plays a conspicuous role in regulating apoptosis
during the embryogenesis in which its expression leads to
developing the proper phenotype of several human fetal
tissues such as kidney, liver, gastrointestinal tract, brain
and lung (Adida et al., 1998). Whereas its expression is
almost undetectable in finally differentiated healthy tis-
sues (Ambrosini et al., 1997). Survivin overexpression has
been detected in most cancers, enables cancer cells to
avoid apoptosis, and increases cell proliferation, tumor
aggressiveness, cancer relapse, and chemotherapy resis-
tance (Li et al., 1998). In a cancer-screening program, the
National Cancer Institute found survivin expression in all
60 human cancer lines. The highest survivin level for
Fig. 2
Survivin contribution toward the cell division process and inhibition of apoptosis. Survivin participates in cell cycle progression and mitosis through its
role in the chromosomal passenger complex (CPC), which acts as a key regulator of chromosome segregation and cytokinesis. Survivin regulate the
localization of the enzymatic component (Aurora kinase B) toward kinetochores in association with two other CPC complex components: borealin and
inner centromere protein antigen (INCENP). During mitosis, aurora kinase B provides correct chromosomal alignment, segregation, and cytokinesis
thorough its auto-phosphorylation upon recruitment to the CPC complex. After DNA-damaging stress, activation of checkpoint kinase 2 (Chk2) leads
to the rapid release of survivin from the mitochondria, which inhibits cell death and promotes cancer cell survival. Furthermore, stabilization of wild-type
p53 is another result of DNA damage which represses the survivin transcription and assisting to balance this pathway (Mobahat et al., 2014). XIAP,
X-linked inhibitor of apoptosis.
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breast and lung cancer and the lowest level for renal
cancer were reported (Kusner et al., 2014; Ue et al., 2014).
Thus, survivin is considered a molecular target in cancer
diagnosis and cancer therapy. Different strategies have
been applied to reduce survivin expression and even
sensitize cancer cells to anticancer drugs. Therefore,
utilizing the RNA interfering mechanism, antisense oli-
gonucleotides, ribozyme approach, and other inhibitors of
survivin are described below.
RNA-interfering survivin knockdown
The regulatory mechanism of RNAi (RNA interference)
uses synthetic short RNAs duplex, which inhibits specific
gene expression. Since the discovery of RNAi, many
attentions have been attracted on its possible therapeutic
application. Researchers have used small interfering
RNA (siRNA) and short hairpin RNA to knock down
survivin expression (Ambrosini et al., 1997; Pennati et al.,
2007). Carvalho et al. (2003) first applied RNAi to sup-
press Survivin expression in HeLa cells, which resulted
in cell accumulation in the prometaphase with delayed
mitosis and misaligned chromosomes. It has been shown
in several studies that the use of survivin-targeted siRNA
or a vector coding for short hairpin RNA could reduce
cell viability through activation of caspase-3 and caspase-
7 at high levels and induces cell apoptosis subsequently
(Nakao et al., 2006; Arami et al., 2017; Huang et al., 2017;
Liu et al., 2017; Wang et al., 2017a; Ye et al., 2017).
However, greater therapeutic effects may be achieved if
the survivin-silencing strategy is combined with che-
motherapy agents such as vinblastine (Trabulo et al.,
2011), doxorubicin (Trabulo et al., 2011; Li et al., 2017),
vincristine (Jiang et al., 2006), 5-fluorouracil (AlShamaileh
et al., 2017), and paclitaxel (PXL) (Chen et al., 2017; Gu
et al., 2017) because of the enhanced cell susceptibility to
these treatments after survivin downregulation. In
another study, survivin interference in HeLa cells not
only inhibited cell proliferation but also enhanced
radiosensitivity (Song et al., 2008).
Antisense oligonucleotide
Short single-strand DNA or RNA with a length of 13–20
bases, complementary to a single strand RNA, blocks spe-
cific gene expression and the protein products are subse-
quently known as antisense oligonucleotides (ASOs).
Binding of ASOs with its target mRNA recruits RNase H,
which recognizes and cleaves the RNA strand within the
ASO–mRNA complex (Biroccio et al., 2003). ASOs are
delivered to cells as chemically synthesized agents or
through the ASO-expressing vectors. ASO-based survivin
downregulation reduces cell proliferation, induces caspase-
dependent cell apoptosis, and inhibits the tumor growth
rate (Ansell et al., 2004; Fuessel et al., 2004; Sharma et al.,
2005; Du et al., 2006). In another study by Sharma et al.
(2005) ASOs sensitizes head and neck squamous cell car-
cinomas cells to cisplatin and etoposide as chemotherapy
drugs, which leads to lower dose consumption of
chemotherapy agents. Two common ASOs are described
here: LY2181308 and SPC3042. LY2181308 is a 2′-O-
methoxymethyl modified antisense oligonucleotide devel-
oped by Eli Lilly (ISIS 23722; Eli Lilly and Co. and ISIS
Pharmaceuticals Inc.), used in both SW480 colorectal SW40
xenograft model to investigate whether the survivin
attenuation by LY2181308 enhances radiation responses.
LY2181308 effectively radiosensitized colorectal cancer
cells in both SW40 cell culture and xenograft model (Rodel
et al., 2008). Successful preclinical outcomes led to clinical
testing of this antisense oligonucleotide. In patients with
acute myeloid leukemia, LY2181308 inhibited survivin
expression and more synergistic effects were also achieved
after combining LY2181308 with cytarabine and idarubicin
(Erba et al., 2013). The results of the LY2181308 application
on patients with advanced solid tumors were not promising,
neither when LY2181308 used alone in a phase I trial
(Tanioka et al., 2011) nor in combination with other agents
such as docetaxel/prednisone in phase II trial (Wiechno
et al., 2014), which shows the limited potential of this
strategy for aggressive solid tumor treatment. Because of
the low stability and efficient neutralization of target
mRNA by ASOs, Fisker et al. (2007) designed SPC3042
with higher stability that is presented as a locked nucleic
acid-modified ASO. SPC3042 was found to be more effi-
cient for survivin inhibition, and also enhanced the
response of prostate cancer cells to taxol.
Ribozyme approach
Ribozymes are small RNA molecules that cleave RNA
targets by their specific endonucleolytic activity. In par-
ticular, hammerhead ribozyme has a conserved catalytic
core that cleaves the RNA target at the 3′ end of NHH
triplet at the second H position, whereas N can be any
nucleotide and H is any nucleotide, except guanidine
(Wang et al., 2007). It has been discovered in multiple
studies that ribozyme-mediated survivin downregulation
inhibits the antiapoptotic function of survivin (Choi et al.,
2003), and increases both spontaneous and drug-induced
apoptosis, with a reduction in the tumorigenic potential
of cancer cells (Pennati et al., 2004a). Pennati et al. (2003)
used the pRC/CMV vector coding for a ribozyme
sequence; the CUA110 triplet in the survivin mRNA was
targeted by indicated ribozyme, and more cell suscept-
ibility to gamma radiation and radiation-induced apop-
tosis in human melanoma cells was detected. In another
In another study by this author, two active (RZ/survivin)
and mutant (mutRZ/survivin) form of hammerhead
ribozyme were generated and transfected to the JR8
human melanoma cell line to downregulate the survivin
expression. The RZ/survivin targets the 3' end of
GUC294 triplet in the exon 3 of survivin mRNA while
the mutRZ/survivin carries a mutation in the catalytic
core. The significant survivin downregulation was
observed in the JR8-RZ/survivin cells. Furthermore, in
the xenograft model, compared to the JR8-mutRZ/sur-
vivin cells, the JR8-RZ/survivin cells showed more
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Table 1 List of compounds in cancer prevention with different substances led to the downregulation of survivin expression
Compound name Type of compound Cancer type Function and effects References
Berberine Isoquinoline alkaloid (botanical drug) Human eryhromyeloblastoid leukemia cell line
(K562)
Suppression of survivin and iNOS through inhibition of NF-κB
expression
Antiproliferative, anti-inflammatory, and cytotoxic effect
Apoptosis induction by survivin downregulation
Pazhang et al. (2011)
Dihydromyricetin Natural flavonoid Ovarian cancer cell line (A2780) P-53-mediated survivin downregulation
Suppress cell proliferation
Cell sensitizing to both PXL and DOX
Apoptosis induction
Xu et al. (2017)
Celecoxib and dimethyl-celecoxib Coxib Most cell lines including the colon carcinoma
and the glioblastoma cell line
Survivin downregulation through inhibition of its promoter activity
Glioma cell chemosensitizing to irinotecan (CPT-11) as an
anticancer agent inhibiting tumor growth
Apoptosis induction
Pyrko et al. (2006)
Epigallocatechin-3-gallate Polyphenol (derived from green tea) Gastric cancer cell lines (NUGC-3, MKN-1) Inhibiting survivin expression through P73 activation
Suppressing cell growth by inhibiting NF-κB, AKT signaling, p53
and p73 activation
Apoptosis induction
Onoda et al. (2011)
Fasaplysin Planar, aromatic compound derived from murine
sponge, a CDK4 inhibitor
Lung cancer cells Apoptosis induction through survivin and HIF-α downregulation
and inhibition of VEGFR2 and TRKA
Oh et al. (2017)
Morusin Natural compound derived from the root bark of
Morus alba (white mulberry)
Breast cancer cell line (MCF-7, MDA-MB) Survivin downregulation
Inducing proapoptotic protein BAX
Anticancer effect by inhibiting NF-κB pathway and STAT-3,
which leads to cell apoptosis
Kang et al. (2017)
Olanzapine Atypical antipsychotic, thienobenzodiazepine Lung and pancreatic CSCs including A549
CSLC, PANC-1 CSLC
Survivin downregulation
Sensitizing A549 CSLC to gemcitabine, as a chemotherapeutic
agent
Sanomachi et al. (2017)
Aripiprazole Atypical antipsychotic, partial dopamine
antagonist
Lung and pancreatic CSCs Survivin downregulation
Cell sensitizing to 5-FU, gemcitabine, and cisplatin
Growth-inhibitory effect
Induce CSCs differentiation to non-CSCs
Suzuki et al. (2016)
Aspirin (acetylsalicylic acid) NSAID Gastric carcinoma cells Survivin downregulation through inducing survivin pro easomal
degradation and inhibition of E2-F-1 binding to the survivin
promoter
Inhibition of cell proliferation and TRAIL-induced apoptosis
promotion because of survivin reduction
Lu et al. (2008); Yoo and Lee
(2007); Yang et al. (2011)
Dequelin Rotenoid derived from Mundulea sericea T-cell leukemia cell line (KUT-1, MT-2) Inhibition of HSP90, which promotes ubiquitin-mediated survivin
degradation
Inhibition of STAT-3 phosphorylation
Decreasing cell proliferation
Apoptosis induction
Ito et al. (2010)
IFN-γ and dehydroxymethyl-
epoxyquinomicin
IFNs DHMEQ: NF-κB inhibitor Renal cell carcinoma (KU19-20) Survivin downregulation through inhibition of NF-κB
IFN-γ and DHMEQ showed a synergistic effect on inhibition of
cell proliferation
Sato et al. (2006)
Quercetin Flavonoid SW480 colon cancer Antitumor activity through downregulation of survivin, cyclin D1,
and the Wnt/B-catenin pathway
Decreasing cell viability
Inducing cell-cycle arrest and apoptosis
Shan et al. (2009)
Sorafenib Multikinase inhibitor Non-small-cell lung cancer (H1299, A549) Downregulation of survivin through Redd1-induced inhibition of
mTOR
Cell sensitizing to TRAIL-induced apoptosis
Kim et al. (2011)
Tamoxifen Nonsteroidal antiestrogen Hepatocellular carcinoma cell line (Hep G2) Reducing cell proliferation at a concentration of ≥10 μmol/l
Cytocide effect and apoptosis induction because of survivin
downregulation
Guo et al. (2009)
CSC, cancer stem cell; DHMEQ, dehydroxymethyl-epoxyquinomicin; DOX, doxorubicin; 5-FU, 5-fluorouracil; HSP90, heat shock protein 90; IFN, interferon; iNOS, inducible nitric oxide synthase; mTOR, mammalian target of
rapamycin; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; PXL, paclitaxel; Redd1, regulated in development and DNA damage responses; STAT, signal transducer and activator of transcription 3; TRIAL,
TNF-related apoptosis-inducing ligand.
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sensitivity to the topotecan as inhibitor of topoisomerase-1
(Pennati et al., 2004b). Thus, these studies used a
ribozyme-mediated survivin inhibition approach to
achieve more radiosensitization and chemosensitization
in cancer cells. Along with the beneficial effects of ribo-
zymes, a few major problems including RNA degradation,
misfolding, and improper cell trafficking have hindered
the therapeutic application of ribozymes in medicine. In
an attempt to circumvent this, Liu et al. (2007) designed
a chimeric pRNA/ribozyme in which the motor pRNA
from bacteriophage phi29 was used as ribozyme carrier.
The motor pRNA molecule comprises of an interlocking
loop domain and a 5'/3' helical domain with independent
folding. After the ribozyme connection to the helical
domain, the pRNA/ribozyme chimer recognizes into a
circularly permuted form with relocated 5'/3' ends. Finally,
the chimeric pRNA/ribozyme with proper folding and
increased stability leads to effective silencing of survivin
gene at both RNA and protein level.
Survivin inhibitors
YM155 (sepantronium bromide) is the first and most
recognized inhibitor of survivin, which binds directly to
the survivin promoter and suppresses its transactivation
(Nitta et al., 2017). As the basal expression of survivin is
related to binding of specificity protein 1 (SP1) to the
GC-rich region of the survivin promoter (Li and Altieri,
1999), inhibition of survivin transcription through dis-
ruption of the SP1–DNA interaction by YM155 was also
reported by Cheng et al. (2012). The ability of YM155 to
induce tumor regression in multiple xenograft models of
cancer was proved (Nakahara et al., 2007; Kita et al., 2011;
Yamanaka et al., 2011); furthermore, in comparison with
monotherapy, YM155 combination with platinum com-
pounds (cisplatin and carboplatin) (Iwasa et al., 2010) and
docetaxel (Nakahara et al., 2011; Yamanaka et al., 2011)
was found to be superior. As heat shock protein 90
(HSP90) protects ubiquitin-mediated survivin degrada-
tion in the G1 phase, the second survivin inhibitor
focuses on the survivin–HSP90 interaction. Shepherdin
antagonizes HSP90–survivin binding, and also acts as a
global HSP90 inhibitor by competition with ATP, which
leads to apoptosis, and inhibited the growth of the
xenograft model of prostate and breast cancer (Plescia
et al., 2005). Tetrameprocol [meso-tetra-O-methyl nor-
dihyroguaiaretic acid (M4N)], also known as EM-1421, is
another molecules that prevents SP1-dependent survivin
transcription, which induces growth arrest and cell
apoptosis in transformed cells (Chang et al., 2004). Felix
et al. (2013) also proposed SF002-96-1 as a new survivin
inhibitor. SF002-96-1 is a drimane sesquiterpene lactone
isolated from Aspergillus species, which decreased survi-
vin mRNA and protein levels by preventing the binding
of transcriptional factors signal transducer and activator of
transcription 3 and nuclear factor κ-light-chain-enhancer
of activated B cells to the survivin promoter and triggered
apoptosis subsequently. FL118 is another substance used
in the treatment of lung cancer stem cells (CSCs) by
Wang et al. (2017b). FL118 treatment led to a reduction
in survivin in CSCs, downregulation of CSCs markers
(such as ABCG2 and Oct4) and drug-resistance asso-
ciated proteins (such as P-glycoprotein), and decreased
the invasive ability of CSCs. These results suggest that
FL118 could be useful in the phenotype alteration of
CSCs and improvement of drug sensitivity in tumor cells.
GDP366 is also another compound that acts by decreas-
ing the survivin mRNA and protein and affects P53 and
P21 levels too. GDP366 is responsible for polyploidy,
chromosomal instability, and cellular senescence through
inhibition of the telomerase activity (Shi et al., 2010).
Among the many identified anticancer drugs, PXL has
been introduced as an effective drug on survivin. PXL is
a first-line anticancer drug with inhibitory effects on
cancer cell proliferation, invasion, and migration (Terzis
et al., 1997). Moreover, PXL is a mitotic inhibitor and
stabilizes the microtubule structure through excitron
protein synthesis, which binds to microtubules and pre-
vents its depolymerization (Gu et al., 2017). It is note-
worthy that one of the drawbacks in the cancer treatment
regimen is tumor cell drug resistance; to circumvent this,
researchers used combined therapy, which involves the
application of both siRNA-targeted survivin and PXL as
a chemotherapy agent in the treatment of multiple cancer
cells. Chen et al. (2017) designed a liposome-based
nanosystem for siRNA and PXL codelivery to breast
cancer cells. Survivin downregulation sensitized cells to
PXL and inhibited their growth and metastasis potential.
In other studies, survivin reduction by siRNA facilitated
PLX-induced apoptosis and reversed drug resistance
similarly (Kar et al., 2015; Salzano et al., 2015; Gu et al.,
2017). However, other compounds with a specific role in
cancer prevention by downregulation of the survivin
expression are also listed in Table 1.
Conclusion
Nowadays, the specific goal in cancer therapy is to
identify how to induce cancer cell death or make the cells
more sensitive to anticancer drugs, chemotherapy, and
radiotherapy. Survivin, a unique member of the IAP
family, prevents cell apoptosis by inhibiting caspase
function. However, its role in cell-cycle progression and
cell division has also been identified. Survivin has an
aberrant expression in cancer cells, which leads to tumor
progression, a poor prognosis, and therapeutic resistance
in these cells. In terms of the difference between normal
and cancer tissues in survivin expression, which can act as
a tumor biomarker, researches have focused on targeting
the survivin expression using multiple approaches men-
tioned above. In addition, survivin measurement can be
useful in cancer diagnosis, prognosis, and predicting
likely resistance or response to therapeutic approaches.
According to previous studies in cancer prevention with a
focus on survivin expression, evidences show that inhi-
bition of survivin may lead to spontaneous apoptosis,
6 European Journal of Cancer Prevention 2018, Vol 00 No 00
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which is also consistent with more cell sensitivity to
therapeutic approaches. Finally, survivin may be valuable
in both cancer treatment and cancer prevention.
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